Uncategorized - Panthera Bio

Panthera Biopartners appoints Martyn Jellett as Associate Director Business Development to support growing commercial team

April 2, 2024March 27, 2024

Independent clinical trial SMO (Site Management Organisation) Panthera Biopartners has appointed Martyn Jellett as Associate Director Business Development to support its expanding commercial team as the company continues to prosper and expand. Martyn has over 25 years experience in professional sales and business development and has extensive knowledge of the pharmaceutical and medical industry. Panthera, …

International Clinical Trials (ICT): Panthera interview

March 14, 2024March 1, 2024

International Clinical Trials (ICT): Panthera interview – Private vs public vaccine studies, how SMOs can secure the future of UK clinical trials Panthera’s Ian Smith and Chris Dodd recently spoke to ICT about the differences in private versus public clinical trials, how speed is key in preclinical processes and how the UK can improve its …

Panthera contributes to Lord O’Shaughnessy’s independent review into UK clinical trials

July 20, 2023March 27, 2023

Lord James O’Shaughnessy, former Health Minister, has been appointed by the UK government to conduct an independent review of the country’s commercial clinical trials landscape. The review will advise on how to resolve key challenges in conducting commercial clinical trials and ensure that the UK remains a global leader in the field. Lord O’Shaughnessy’s advice is expected to be published this spring.

Panthera Biopartners raises £10 million to accelerate its dedicated clinical trial site expansion

October 11, 2022April 11, 2022

Panthera Biopartners raises £10 million to accelerate its dedicated clinical trial site expansion across the UK and Western Europe Panthera Biosciences (Panthera) has secured £10 million of investment from BGF and Gresham House Ventures, the latter investing on behalf of the Baronsmead VCTs. This investment will allow Panthera to further grow its network of dedicated …

Valneva vaccine clinical trial, phase 3 results

August 25, 2023December 4, 2021

Valneva have released results from their phase 3 vaccine study (VLA2001). Stating that the trial has successfully met both co-primary end points. This trial compared the efficacy and effectiveness of the Valneva Covid-19 vaccine against the AstraZeneca vaccine. A total of 4012 people, aged 18 years and above were recruited to this clinical trial, across …

Panthera becomes the world’s first clinical trial site to administer Valneva’s inactivated COVID-19 vaccine to volunteers in COVID prevention study

August 25, 2023May 20, 2021

This month we have been busy vaccinating volunteers in North Manchester, Preston and North London for a new COVID prevention study. It has been an exciting time as we were the world’s first clinical trial site to administer the vaccine to volunteers in this study. The first participant to be vaccinated at our Rochdale clinic …

Clinical trial specialist Panthera Biopartners has appointed corporate financier Christopher Steed as a non-executive director to continue its expansion both in the UK and overseas

August 25, 2023April 6, 2021

Independent clinical trial site management organisation (SMO), Panthera Biopartners, has appointed M&A and fundraisings adviser Chris Steed as a non-executive director. Chris has over 25 years’ experience as a corporate financier, working at Arthur Andersen, Deloitte and for the past 17 years as Founder and Managing Partner of Argyll Partners. Chris has acted as lead advisor …

Panthera adapts for COVID-19 virus – Letter from Stuart Young, CEO

August 25, 2023May 4, 2020

As we all continue to adapt to the COVID-19 pandemic, we at Panthera are closely monitoring this rapidly evolving situation as well as remaining vigilant to support our patients and the NHS in any way we can. Panthera sites will remain open for business with significant additional precautions to prevent transmission of the COVID-19 virus. …

Work with Us